Literature DB >> 19161866

Evaluation and treatment of hypotension in the preterm infant.

E M Dempsey1, K J Barrington.   

Abstract

A large proportion of very preterm infants receive treatment for hypotension. The definition of hypotension is unclear, and, currently, there is no evidence that treating it improves outcomes or, indeed, which treatment to choose among the available alternatives. Assessment of circulatory adequacy of the preterm infant requires a careful clinical assessment and may also require ancillary investigations. The most commonly used interventions, fluid boluses and dopamine, are problematic: fluid boluses are statistically associated with worse clinical outcomes and may not even increase blood pressure, whereas dopamine increases blood pressure mostly by causing vasoconstriction and may decrease perfusion. For neither intervention is there any reliable data showing clinical benefit. Prospective trials of intervention for hypotension and circulatory compromise are urgently required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161866     DOI: 10.1016/j.clp.2008.09.003

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  13 in total

1.  Association of necrotizing enterocolitis with anemia and packed red blood cell transfusions in preterm infants.

Authors:  R Singh; P F Visintainer; I D Frantz; B L Shah; K M Meyer; S A Favila; M S Thomas; D M Kent
Journal:  J Perinatol       Date:  2011-01-27       Impact factor: 2.521

2.  Accuracy of non-invasive blood pressure monitoring in very preterm infants.

Authors:  Kai König; Dan M Casalaz; Emily J Burke; Andrew Watkins
Journal:  Intensive Care Med       Date:  2012-03-06       Impact factor: 17.440

3.  Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants: authors' reply.

Authors:  Ori Hochwald; Gustavo Pelligra; Horacio Osiovich
Journal:  Indian J Pediatr       Date:  2013-11-06       Impact factor: 1.967

4.  Noradrenaline in preterm infants with cardiovascular compromise.

Authors:  Kirsten Rowcliff; Koert de Waal; Abdel-Latif Mohamed; Tejasvi Chaudhari
Journal:  Eur J Pediatr       Date:  2016-10-15       Impact factor: 3.183

5.  Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy.

Authors:  Jing Chen; Jean-Sebastian Joyal; Colman J Hatton; Aimee M Juan; Dorothy T Pei; Christian G Hurst; Dan Xu; Andreas Stahl; Ann Hellstrom; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

6.  Effects of Prophylactic Indomethacin on Vasopressor-Dependent Hypotension in Extremely Preterm Infants.

Authors:  Melissa Liebowitz; Jane Koo; Andrea Wickremasinghe; Isabel Elaine Allen; Ronald I Clyman
Journal:  J Pediatr       Date:  2016-12-01       Impact factor: 4.406

7.  Early blood pressure, antihypotensive therapy and outcomes at 18-22 months' corrected age in extremely preterm infants.

Authors:  Beau Batton; Lei Li; Nancy S Newman; Abhik Das; Kristi L Watterberg; Bradley A Yoder; Roger G Faix; Matthew M Laughon; Barbara J Stoll; Rosemary D Higgins; Michele C Walsh
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2015-11-13       Impact factor: 5.747

8.  Early postnatal hypotension is not associated with indicators of white matter damage or cerebral palsy in extremely low gestational age newborns.

Authors:  J W Logan; T M O'Shea; E N Allred; M M Laughon; C L Bose; O Dammann; D G Batton; K C Kuban; N Paneth; A Leviton
Journal:  J Perinatol       Date:  2011-01-27       Impact factor: 2.521

9.  On the use of antiangiogenetic medications for retinopathy of prematurity.

Authors:  Anna-Lena Hård; Ann Hellström
Journal:  Acta Paediatr       Date:  2011-05-13       Impact factor: 2.299

Review 10.  Non-dialytic management of acute kidney injury in newborns.

Authors:  Vishal Pandey; Deepak Kumar; Prashant Vijayaraghavan; Tushar Chaturvedi; Rupesh Raina
Journal:  J Renal Inj Prev       Date:  2016-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.